Imaging Drugs Panel to Review NX Development Imaging Agent
Federal Register notice: FDA has announced a 5/10 Medical Imaging Drugs Advisory Committee meeting that will discuss a NX Development Corp. NDA for 5-aminolevulinic acid hydrochloride for the proposed indication as an imaging agent to assist in real time detection and visualization of malignant tissue during glioma surgery. To view the notice, click here.